Recent

% | $
Quotes you view appear here for quick access.

Sanofi Message Board

scistats 381 posts  |  Last Activity: 13 hours ago Member since: Apr 5, 2009
  • Reply to

    Biotechnology stocks feel the Hillary "Bern"

    by scistats Jan 28, 2016 10:29 AM
    scistats scistats Jan 28, 2016 11:23 AM Flag

    Only in America:
    "In a first of its kind collaboration with Arizona State University, we’re offering all part- and full-time benefits eligible U.S. partners full tuition coverage for every year of college to earn a bachelor’s degree. Partners receive support from a dedicated team of coaches and advisors, 24/7 tutoring on a variety of subjects, and a choice of more than 50 undergraduate degrees through ASU's research driven and top-ranked program, delivered online."

    Sentiment: Strong Buy

  • Reply to

    Biotechnology stocks feel the Hillary "Bern"

    by scistats Jan 28, 2016 10:29 AM
    scistats scistats Jan 28, 2016 11:19 AM Flag

    40% taxes in Germany.
    Either you don't work and get it for free, or you do work and give it all away to educate foreigners (many Germans themselves do not even go to college).
    Germany has historically always made the right decisions....right!
    Working through college is part of the education.

    Sentiment: Strong Buy

  • Reply to

    Biotechnology stocks feel the Hillary "Bern"

    by scistats Jan 28, 2016 10:29 AM
    scistats scistats Jan 28, 2016 10:33 AM Flag

    Sell all of you stock now and donate the meager proceeds to Hillary-Bern for President and receive a free bumper sticker (come with large hole drilled in the center).

    Sentiment: Strong Buy

  • Hillary and Bernie have the same plan: Pay for free, comprehensive healthcare using Big Pharma's money.
    Socialism here we come!

    Sentiment: Strong Buy

  • scistats scistats Jan 28, 2016 9:29 AM Flag

    Mixed messages.

    "Facebook Profit Tops $1 Billion
    Revenue grows by 52%; shares climb after hours"

    "Ford posted a record profit for 2015, helped by rising U.S. sales and an end to years of losses in Europe.
    The No. 2 U.S. automaker earned a pre-tax profit for the year of $10.8 billion, and net income of $7.4 billion. Fourth quarter earnings were nearly double results from a year ago."

    Sentiment: Strong Buy

  • General market sentiment is turning positive on bargains and profit makers.
    Onivyde will have to earn its keep with dollars in the bank rather than on analysts lips.

    Sentiment: Strong Buy

  • Reply to

    What happened

    by shoenfield Jan 26, 2016 8:20 PM
    scistats scistats Jan 27, 2016 2:34 PM Flag

    The Dems have made it crystal clear that they plan to socialize medicine, schools, and low income jobs. The only firewall is Gen. Donald "Patton" Trump.

    Sentiment: Strong Buy

  • Reply to

    What happened

    by shoenfield Jan 26, 2016 8:20 PM
    scistats scistats Jan 27, 2016 2:29 PM Flag

    Come on, you know after the Onivyde approval bear raid before the market crash that MACK is highly manipulated and a stop loss would be suicide on a good day. The entire market was shorted by the big boys day one of 2016 an election years filled with anxiety that is a perfect setup for this.

    Sentiment: Strong Buy

  • Reply to

    What happened

    by shoenfield Jan 26, 2016 8:20 PM
    scistats scistats Jan 27, 2016 1:17 PM Flag

    What happened?
    52 week low?
    Shoenfield short?

    Sentiment: Strong Buy

  • Reply to

    What happened

    by shoenfield Jan 26, 2016 8:20 PM
    scistats scistats Jan 27, 2016 12:04 PM Flag

    Well, shoenfield, it started with a tweet from dear, sweet Hillary. Then, the Chinese liked a strong dollar, and gas was too cheap for ISIS to buy iPhones. "The Bern" forced a liquidation of accounts to pay for a National Healthcare Program that includes a daily MRI, a prostate milking (two on Wednesdays), and a foot rub. You are allowed to bring one firearm to the prostate milking, but you have to prove that you disposed of all of your MACK shares. Other than this, comrade, why did you ask? You like new system, no?

    Sentiment: Strong Buy

  • Reply to

    Big Event in NYC

    by wall_street_titan Jan 26, 2016 10:04 AM
    scistats scistats Jan 27, 2016 6:57 AM Flag

    Hmmm, sounds like the ARDS trial in the UK may be working....AMI,Estimated Primary Completion Date: July 2016? Something is up beyond just the Athersys-Healios partnership. Good to keep in mind Healios also wanted ARDS.

    Sentiment: Strong Buy

  • scistats scistats Jan 26, 2016 12:20 PM Flag

    Asking what? I cited a peer-reviewed paper and questioned the possibility of putting combinations in the same or blended liposomes? There are published reports of 5-fluorouracil in liposomes and oxaliplatin as well. What is your organic/pchem concern that limits putting all drugs on target. One group claims to have done this using multiple layer-by-layer lipid-polymer hybrid. I am asking what is your take, why did Merrimack stop with irinotecan and why was it chosen? What is the next generation going to look like?

    Sentiment: Strong Buy

  • scistats scistats Jan 26, 2016 10:19 AM Flag

    nitabosco, just for debate, I am asking: Is it possible to produce a FIRINOX combination in a single Merrimack liposome or produce a blend of the three agents packaged separately?

    The reason I ask is:
    A recent publication states, "nanocarriers (Multiple Layer-by-Layer Lipid-Polymer Hybrid ) were loaded with THE THREE active antitumor constituents of FOLFIRINOX regimen...cargoes were quickly released after the nanoparticles were taken up by tumor cells. These innovative drug-loaded nanoparticles achieved higher antitumor efficacy and showed minimal side effects compared with the FOLFIRINOX regimen alone. (Advanced Functional Materials, Volume 25, Issue 5, pages 788–798, February 4, 2015)

    Note: The FOLFIRINOX regimen is a combination of three chemotherapy agents (5-fluorouracil, irinotecan, oxaliplatin) and folinic acid (a vitamin B derivatives reducing the side effect of 5-fluorouracil)

    What is Onivyde 2.0 or will there be no Onivyde 2.0 but rather a technology leapfrogging by a technology that delivers combinations on target rather than just irinotecan?

    Data suggests Nab-paclitaxel (nanoparticle albumin–bound paclitaxel ) + Gemcitabine after FOLFIRINOX but not before offers a benefit. Can these be packaged as well?

    Sentiment: Strong Buy

  • scistats scistats Jan 26, 2016 9:54 AM Flag

    Big pharma is always betting on "wild things", but GSK's bet on Notch 3 seems too wild. Merrimack is going after established targets. The problem is, so is everyone else. On the positive side, Merrimack's antibodies seem to be working, and they already have a winner with Shire. MM-141 is a fine lad for a rich family's daughter. You cannot rush romance.

    Sentiment: Strong Buy

  • scistats scistats Jan 25, 2016 8:43 PM Flag

    Merrimack has better cancer targets that seem to work based on the data they have gathered. Their targets are well established in cancer and make sense.

    Sentiment: Strong Buy

  • scistats scistats Jan 25, 2016 8:42 PM Flag

    Back in 2000, Notch3 had never before been implicated in human cancer. Nevertheless, probably based on bad mouse or cell culture data, OncoMed and GSK were led to believe it may be a good protein to target for cancer. Turns out it it not. Targeting it does not work. It is hard to believe GSK pursued this.

    Sentiment: Strong Buy

  • scistats scistats Jan 25, 2016 8:30 PM Flag

    I think the OncoMed strategy parallels that of Merrimack.

    They used an antibody to block a target in an attempt to disrupt cancer. Their strategy involved using markers. However, Notch3 was a wildcat target that GSK bet on.

    Merrimack's HER2,3 and EGFR and IGF-1R targets are logical, and the data supports efficacy in the patient subset positive for the marker.

    Both companies have the same idea, like putting a rocket on the moon, but Merrimack's target are working.

    Time for GSK to pick a new horse to bet on?

    Sentiment: Strong Buy

  • Reply to

    Yes or No???

    by eastcoastcash Jan 23, 2016 11:11 AM
    scistats scistats Jan 25, 2016 9:05 AM Flag

    MACK could win a bidding war vs. JUNO?
    Now that's what I call a positive attitude.
    I am angry MACK didn't find CRISPR and beat everyone to the punch for PCYC.
    It is shameful!!!

    Sentiment: Strong Buy

  • scistats scistats Jan 25, 2016 8:57 AM Flag

    Strange target???

    "In Drosophilia, notch interaction with its cell-bound ligands (delta, serrate) establishes an intercellular signalling pathway that plays a key role in neural development. Homologues of the notch-ligands have also been identified in human, but precise interactions between these ligands and the human notch homologues remains to be determined. Mutations in NOTCH3 have been identified as the underlying cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). [provided by RefSeq, Jul 2008]"

    Neurogenic locus notch homolog protein 3 is a protein that in humans is encoded by the NOTCH3 gene.

    This gene encodes the third discovered human homologue of the Drosophilia melanogaster type I membrane protein notch. In Drosophilia, notch interaction with its cell-bound ligands (delta, serrate) establishes an intercellular signalling pathway that plays a key role in neural development. Homologues of the notch-ligands have also been identified in human, but precise interactions between these ligands and the human notch homologues remains to be determined.

    Sentiment: Strong Buy

  • scistats scistats Jan 25, 2016 8:54 AM Flag

    This is relevant to MACK:

    OncoMed Pharmaceuticals Inc. stock OMED, -40.07% plunged 37% in pre-market trade Monday, after an independent data safety monitoring board advised "of several findings regarding futility" of a Phase 2 clinical trial for a treatment of pancreatic cancer. The findings included a worsening of response rate and a strong trend toward a lack of benefit for overall survival. OncoMed said it is considering what to do next. Tarextumab is a product of a collaboration between OncoMed and GlaxoSmithKline GSK.

    Tarextumab (anti-Notch2/3, OMP-59R5) is a novel anti-cancer stem cell antibody that prevents signaling through both the Notch2 and Notch3 receptors. Tarextumab has been shown in preclinical models to inhibit cancer stem cell growth, and promote cell differentiation, as well as disrupt tumor angiogenesis by inhibiting vascular pericytes.

    Tarextumab is currently being studied in two randomized Phase 2 clinical trials. The ALPINE trial is assessing tarextumab with Abraxane plus gemcitabine in first-line advanced pancreatic cancer patients.

    In small cell lung cancer, tarextumab has demonstrated dose-dependent and biomarker driven activity. In pancreatic cancer, anti-tumor responses and prolonged survival rates versus standard of care were observed, particularly in patients whose tumors were identified as high in Notch3 gene expression using OncoMed’s biomarker assay.

    Sentiment: Strong Buy

SNY
38.37-0.12(-0.31%)Feb 11 4:02 PMEST